Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

348
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
348
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

109
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
109
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

162
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
162
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

85
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
85
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

209
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
209
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

365
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
365
  1. Home
  3. Research Domains
  5. Health Sciences
  7. Epidemiology
  9. Epidemiological Modelling
  11. Risk Of Map-like Redness Development After Eradication Therapy For Helicobacter Pylori Infection.

Risk of map-like redness development after eradication therapy for Helicobacter pylori infection.

Sho Matsumoto1, Mitsushige Sugimoto2, Masakatsu Fukuzawa1

  • 1Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.

Helicobacter
|July 10, 2024

Related Experiment Videos

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

304
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.0K
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

191

View abstract on PubMed

Summary
This summary is machine-generated.

Map-like redness, a risk factor for gastric cancer after H. pylori eradication, occurs in about a quarter of patients. Severe intestinal metaplasia and acid inhibitor use are linked to its development, warranting closer surveillance.

Area of Science:

  • Gastroenterology
  • Oncology
  • Endoscopy

Background:

  • Map-like redness is a newly identified endoscopic risk factor for gastric cancer following H. pylori eradication.
  • The incidence and risk factors for map-like redness post-eradication are not well understood.

Purpose of the Study:

  • To determine the incidence of map-like redness one year after H. pylori eradication.
  • To evaluate associations between map-like redness, gastric condition, and gastric cancer risk.

Main Methods:

  • Retrospective evaluation of endoscopic gastritis and map-like redness using the Kyoto Classification of Gastritis.
  • Analysis of 328 patients before and after H. pylori eradication therapy.

Main Results:

  • Map-like redness incidence was 25.3% at a mean of 1.2 years post-eradication.
Keywords:
Helicobacter pyloriatrophyeradication therapygastric cancer

Related Experiment Videos

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

304
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.0K
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

191
  • Map-like redness was associated with older age, severe atrophy, intestinal metaplasia, higher Kyoto scores, and gastric cancer history.
  • Risk factors for map-like redness included intestinal metaplasia (OR: 2.794) and acid inhibitor use (OR: 1.948).
  • Gastric cancer risk was elevated in H. pylori-positive patients who were older, took acid inhibitors, and had post-eradication map-like redness.

    • Conclusions:

    • Map-like redness is present in approximately one-fourth of patients one year after H. pylori eradication.
    • Severe intestinal metaplasia and acid inhibitor use are associated with map-like redness development.
    • Patients with map-like redness require increased attention during surveillance endoscopy due to potential gastric cancer risk.
    intestinal metaplasia
    map‐like redness